Live Q&A: From Bench to Bedside: Applying Clinical Updates to Treatment Planning for Patients with Narcolepsy

CMEO Webcast

Premiere Date: Thursday, May 26, 2022

This activity will offer CE credit for:

  1. Medicine (accme)
  2. Nursing (ANCC)
  3. Pharmacy (acpe)
  4. PA (aapa)

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Creditâ„¢

Credit Expiration Date: Friday, May 26, 2023


Michael J. Thorpy, MD Michael J. Thorpy, MD (Moderator)
Professor of Neurology
Albert Einstein College of Medicine
Director, Sleep-Wake Disorders Center
Department of Neurology
Montefiore Medical Center
Bronx, NY
President, New York State Society of Sleep Medicine
Past President of the Sleep Section, Academy of Neurology

Phyllis C. Zee, MD, PhD Phyllis C. Zee, MD, PhD 
Professor of Neurology
Northwestern University Feinberg School of Medicine
Director, Sleep Disorders Center
Northwestern Memorial Hospital
Chicago, IL

Statement of Need

EDS (excessive daytime sleepiness) extends beyond feeling tired or falling asleep during the day and encompasses impaired health-related quality of life (HRQoL) and psychosocial and work functioning. A major factor contributing to the debilitation associated with EDS in patients with narcolepsy is misdiagnosis and diagnostic delays reportedly greater than 10 years. Strategies to enhance early detection are essential to facilitate early treatment intervention to reduce the disease burden.

This live Q&A session is your opportunity to ask faculty experts about the extensive burden imposed by EDS in narcolepsy as well as diagnostic strategies to facilitate early detection and implementation of effective treatment. Join Drs. Thorpy and Zee to learn about best practices and the latest tools to accurately diagnose narcolepsy and ultimately reduce disease burden. To view the full activity ahead of this live Q&A, click here.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Assess the clinical, QoL, and functional burden of EDS and cataplexy in patients with narcolepsy.
  • Enhance the early detection of narcolepsy to facilitate early treatment intervention to reduce disease burden.

Financial Support

Supported by an educational grant from Harmony Biosciences, LLC.

Target Audience

Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in psychiatry and/or primary care

Credit Information

Specific CE Credit information is not available at this time. Please check again soon!

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Thorpy reports the following financial relationships:

Advisory Board/Consultant: Axsome Therapeutics Inc.; Balance Therapeutics; Eisai Inc.; Flamel Technologies/Avadel; Harmony Biosciences, LLC; Jazz Pharmaceuticals, Inc.; NLS Pharmaceutics; Suven Life Sciences Limited; Takeda Pharmaceutical Company Limited; and XWPharma

Dr. Zee reports the following financial relationships:

Consultant: Eisai Inc.; Harmony Biosciences, LLC; Idorsia Pharmaceuticals US Inc.; Jazz Pharmaceuticals, Inc.; Sanofi-Aventis; and Takeda Pharmaceutical Company Limited

Grants: Vanda Pharmaceuticals (Paid to Northwestern University)

The following peer reviewer and CME Outfitters staff have no financial relationships to disclose:

  • Marlon (Tony) Graham, MD (peer reviewer)
  • Kashemi D. Rorie, PhD (planning committee)
  • Evan Luberger (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sharon Tordoff (planning committee)

  • Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

    Questions about this activity? Call us at 877.CME.PROS (877.263.7767).

    This document was last modified on: